J. Carl Barrett

38.7k total citations · 14 hit papers
313 papers, 21.2k citations indexed

About

J. Carl Barrett is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, J. Carl Barrett has authored 313 papers receiving a total of 21.2k indexed citations (citations by other indexed papers that have themselves been cited), including 149 papers in Molecular Biology, 99 papers in Cancer Research and 98 papers in Oncology. Recurrent topics in J. Carl Barrett's work include Cancer Genomics and Diagnostics (58 papers), DNA Repair Mechanisms (37 papers) and Telomeres, Telomerase, and Senescence (31 papers). J. Carl Barrett is often cited by papers focused on Cancer Genomics and Diagnostics (58 papers), DNA Repair Mechanisms (37 papers) and Telomeres, Telomerase, and Senescence (31 papers). J. Carl Barrett collaborates with scholars based in United States, United Kingdom and Japan. J. Carl Barrett's co-authors include Izumi Horikawa, Eriko Michishita, Mitsuo Oshimura, Brian Dougherty, Cynthia A. Afshari, Kenneth S. Thress, Jean Y. Park, Mireille Cantarini, Takeki Tsutsui and Pasi A. Jänne and has published in prestigious journals such as Nature, Science and Proceedings of the National Academy of Sciences.

In The Last Decade

J. Carl Barrett

304 papers receiving 20.6k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

2015 1.2k citations Kenneth S. Thress, Cloud P. Paweletz et al. profile →
Evolutionarily Conserved and Nonconserved Cellular Localizations and Functions of Human SIRT Proteins

2005 1.1k citations J. Carl Barrett, Izumi Horikawa et al. profile →
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial

2014 1.1k citations Jonathan A. Ledermann, Philipp Harter et al. profile →
SIRT6 is a histone H3 lysine 9 deacetylase that modulates telomeric chromatin

2008 855 citations J. Carl Barrett et al. profile →
Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non–Small-Cell Lung Cancer

2016 641 citations Geoffrey R. Oxnard, Kenneth S. Thress et al. profile →
Senescing human cells and ageing mice accumulate DNA lesions with unrepairable double-strand breaks

2004 623 citations Izumi Horikawa, J. Carl Barrett et al. profile →
VarDict: a novel and versatile variant caller for next-generation sequencing in cancer research

2016 497 citations Zhongwu Lai, Brian Dougherty et al. profile →
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial

2014 426 citations Brian Dougherty, J. Carl Barrett et al. profile →
EGFR mutation detection in ctDNA from NSCLC patient plasma: A cross-platform comparison of leading technologies to support the clinical development of AZD9291

2015 401 citations Kenneth S. Thress, Roz Brant et al. profile →
Osimertinib As First-Line Treatment of EGFR Mutation–Positive Advanced Non–Small-Cell Lung Cancer

2017 380 citations Suresh S. Ramalingam, Yuichiro Ohe et al. profile →
Impact of a five-dimensional framework on R&D productivity at AstraZeneca

2018 271 citations J. Carl Barrett et al. profile →
Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study

2018 269 citations Suresh S. Ramalingam, Fumio Imamura et al. profile →
Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer

2023 130 citations Juliann Chmielecki, Jhanelle E. Gray et al. Nature Communications profile →
Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial

2023 95 citations Juliann Chmielecki, Suresh S. Ramalingam et al. Nature Communications profile →

Peers

Countries citing papers authored by J. Carl Barrett

Since Specialization

Citations

This map shows the geographic impact of J. Carl Barrett's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by J. Carl Barrett with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites J. Carl Barrett more than expected).

Fields of papers citing papers by J. Carl Barrett

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by J. Carl Barrett. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by J. Carl Barrett. The network helps show where J. Carl Barrett may publish in the future.

Co-authorship network of co-authors of J. Carl Barrett

This figure shows the co-authorship network connecting the top 25 collaborators of J. Carl Barrett. A scholar is included among the top collaborators of J. Carl Barrett based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with J. Carl Barrett. J. Carl Barrett is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Candidate mechanisms of acquired resistance to first-line osimertinib in EGFR-mutated advanced non-small cell lung cancer breakdown → 2023 ·Nature Communications ·Juliann Chmielecki, Jhanelle E. Gray, Ying Cheng, Yuichiro Ohe, Fumio Imamura, Byoung Chul Cho, Meng‐Chih Lin, Margarita Majem, Riyaz Shah, Yuri Rukazenkov, (unknown), Aleksandra Markovets, J. Carl Barrett, Ryan J. Hartmaier, Suresh S. Ramalingam	130
2	Immune Cell Abundance and T-cell Receptor Landscapes Suggest New Patient Stratification Strategies in Head and Neck Squamous Cell Carcinoma 2023 ·Cancer Research Communications ·Maria Secrier, Lara McGrath, Felicia Ng, Sakshi Gulati, Amelia Raymond, Barrett Nuttall, (unknown), Emma V. Jones, Ben S. Sidders, Jérôme Galon, J. Carl Barrett, Helen K. Angell	7
3	Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitors 2023 ·Journal for ImmunoTherapy of Cancer ·Harriet M. Kluger, J. Carl Barrett, Justin F. Gainor, Omid Hamid, Michael E. Hurwitz, Theresa LaVallee, Rebecca A. Moss, Roberta Zappasodi, Ryan J. Sullivan, Hussein A. Tawbi, Elad Sharon	40
4	Detection of BRCA1 , BRCA2 , and ATM Alterations in Matched Tumor Tissue and Circulating Tumor DNA in Patients with Prostate Cancer Screened in PROfound 2022 ·Clinical Cancer Research ·Kim N., Alan Barnicle, (unknown), Zhongwu Lai, Claire Corcoran, J. Carl Barrett, Carrie A. Adelman, Ping Qiu, Ashley Easter, Simon Dearden, Geoffrey R. Oxnard, Neeraj Agarwal, Arun Azad, Johann S. de Bono, Joaquı́n Mateo, David Olmos, Antoine Thiery-Vuillemin, Elizabeth A. Harrington	46
5	Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis 2021 ·Journal of Visualized Experiments ·Paola Marco‐Casanova, Natalia Lukashchuk, (unknown), Veerendra Munugalavadla, Melanie M. Frigault, Elizabeth A. Harrington, J. Carl Barrett, Andrew J. Pierce	3
6	Validation of ctDNA Quality Control Materials Through a Precompetitive Collaboration of the Foundation for the National Institutes of Health 2021 ·JCO Precision Oncology ·P. Mickey Williams, (unknown), Steven P. Lund, Kenneth D. Cole, Hua‐Jun He, Chris Karlovich, Cloud P. Paweletz, Daniel Stetson, Laura M. Yee, Dana E. Connors, Susan M. Keating, Benoit Destenaves, Megan H. Cleveland, Christie J. Lau, J. Carl Barrett, Gary J. Kelloff, Robert McCormack	14
7	Retrospective analysis of Schlafen11 (SLFN11) to predict the outcomes to therapies affecting the DNA damage response 2021 ·British Journal of Cancer ·Sophie E. Willis, C Winkler, Martine P. Roudier, (unknown), Paola Marco‐Casanova, Emma V. Jones, Philip Rowe, Jaime Rodriguez‐Canales, Helen K. Angell, Felicia Ng, Paul Waring, Darren Hodgson, Jonathan A. Ledermann, Johanne I. Weberpals, Emma Dean, Elizabeth A. Harrington, J. Carl Barrett, Andrew J. Pierce, Elisabetta Leo, Gemma N. Jones	31
8	Prognostic and Predictive Impact of Circulating Tumor DNA in Patients with Advanced Cancers Treated with Immune Checkpoint Blockade 2020 ·Cancer Discovery ·Qu Zhang, Jia Luo, Song Wu, Han Si, Chen Gao, Wenjing Xu, Shaad E. Abdullah, Brandon W. Higgs, Phillip A. Dennis, Michiel S. van der Heijden, Neil H. Segal, Jamie E. Chaft, Todd Hembrough, J. Carl Barrett, Matthew D. Hellmann	221
9	Identification of CCR2 and CD180 as Robust Pharmacodynamic Tumor and Blood Biomarkers for Clinical Use with BRD4/BET Inhibitors 2017 ·Clinical Cancer Research ·Tammie C. Yeh, Greg O’Connor, Philip Petteruti, Austin Dulak, Maureen M. Hattersley, J. Carl Barrett, Huawei Chen	16
10	Clinically Viable Gene Expression Assays with Potential for Predicting Benefit from MEK Inhibitors 2016 ·Clinical Cancer Research ·Roz Brant, Alan Sharpe, (unknown), Jonathan R. Dry, Elizabeth A. Harrington, J. Carl Barrett, Nicky Whalley, Christopher J. Womack, Paul D. Smith, Darren Hodgson	17
11	Reproducible, Quantitative, and Flexible Molecular Subtyping of Clinical DLBCL Samples Using the NanoString nCounter System 2014 ·Clinical Cancer Research ·Margaret H. Veldman-Jones, Zhongwu Lai, Mark Wappett, Chris Harbron, J. Carl Barrett, Elizabeth A. Harrington, Kenneth S. Thress	54
12	Olaparib Maintenance Therapy in Patients With Platinum-Sensitive Relapsed Serous Ovarian Cancer 2014 ·Obstetrical & Gynecological Survey ·Jonathan A. Ledermann, Philipp Harter, Charlie Gourley, Michael Friedländer, Ignace Vergote, Gordon Rustin, Clare L. Scott, Werner Meier, Ronnie Shapira‐Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, Brian Dougherty, Maria Orr, Darren Hodgson, J. Carl Barrett, Ursula A. Matulonis	14
13	PIK3CA Mutations May Be Discordant between Primary and Corresponding Metastatic Disease in Breast Cancer 2010 ·Clinical Cancer Research ·Jeanette Dupont Jensen, Anne‐Vibeke Lænkholm, Ann Knoop, Marianne Ewertz, Raj Bandaru, Weihua Liu, Wolfgang Hackl, J. Carl Barrett, Humphrey Gardner	151
14	A Gene Signature Predicting for Survival in Suboptimally Debulked Patients with Ovarian Cancer 2008 ·Cancer Research ·Tomás Bonome, Douglas A. Levine, Joanna H. Shih, Mike Randonovich, Cindy A. Pise-Masison, Faina Bogomolniy, Laurent Ozbun, John Brady, J. Carl Barrett, Jeff Boyd, Michael J. Birrer	325
15	Gene Expression Profiles of Serous, Endometrioid, and Clear Cell Subtypes of Ovarian and Endometrial Cancer 2005 ·Clinical Cancer Research ·Kristin K. Zorn, Tomás Bonome, Lisa Gangi, Gadisetti V.R. Chandramouli, Christopher S. Awtrey, Ginger J. Gardner, J. Carl Barrett, Jeff Boyd, Michael J. Birrer	282
16	Gene Expression Profiles Associated with Response to Chemotherapy in Epithelial Ovarian Cancers 2005 ·Clinical Cancer Research ·Amir A. Jazaeri, Christopher S. Awtrey, Gadisetti V.R. Chandramouli, (unknown), Javed Khan, Christos Sotiriou, Olga Aprelikova, Cindy J. Yee, Kristin K. Zorn, Michael J. Birrer, J. Carl Barrett, Jeff Boyd	151
17	Expression Profiling of Serous Low Malignant Potential, Low-Grade, and High-Grade Tumors of the Ovary 2005 ·Cancer Research ·Tomás Bonome, (unknown), Dong-Choon Park, Mike Radonovich, Cindy A. Pise-Masison, John Brady, Ginger J. Gardner, Ke Hao, Wing H. Wong, J. Carl Barrett, Karen H. Lu, Anil K. Sood, David M. Gershenson, Samuel C. Mok, Michael J. Birrer	238
18	High-resolution serum proteomic features for ovarian cancer detection. 2004 ·Endocrine Related Cancer ·Thomas P. Conrads, Vincent A. Fusaro, Sally Ross, Don Johann, Vinodh N. Rajapakse, Ben A. Hitt, Seth M. Steinberg, Elise C. Kohn, David A. Fishman, (unknown), J. Carl Barrett, Lance A. Liotta, Emanuel F. Petricoin, Timothy D. Veenstra	210
19	Cellular Senescence Mechanisms Independent of Telomere Shortening and Telomerase: Other Barriers to Cell Immortalization and Carcinogenesis 2000 ·Izumi Horikawa, Toshio Yawata, J. Carl Barrett	8
20	Role of chromosome loss in ras/myc-induced Syrian hamster tumors. 1988 ·PubMed ·Mitsuo Oshimura, Minoru Koi, Nobuki Ozawa, Osamu Sugawara, Patricia W. Lamb, J. Carl Barrett	28

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact